ResMed plans USD 1.5 billion share repurchase and RBC raises target for ResMed stock
Published on 10/06/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed plans a USD 1.5 billion share repurchase program for fiscal year 2027, according to ResMed in a proxy filed on October 1, 2026. Separately, MarketBeat reports that Royal Bank of Canada raised its target for ResMed from USD 244.00 to USD 262.00 on September 15, 2026.
Repurchase plan resets capital returns
The proxy links the repurchase plan to ResMed's fiscal year 2027 capital allocation. The company said it expects to return more than USD 1.85 billion to stockholders in fiscal year 2027, including a 10 percent increase in its quarterly dividend to USD 0.66 per share.
ResMed also completed the sale of its MatrixCare business on September 1, 2026, while using proceeds from that transaction to support an accelerated share repurchase agreement. The capital plan gives the company a second financial lever beyond operating growth, although the filing does not present the repurchase as a substitute for demand expansion.
Fiscal 2026 growth stays measurable
ResMed reported USD 5.7 billion of revenue in fiscal year 2026, up 10 percent on a reported basis and 8 percent in constant currency, according to the October 1, 2026 proxy. Non-GAAP diluted earnings per share grew 17 percent in the same fiscal year, while GAAP operating margin stood at 33 percent.
The latest quarterly comparison adds detail. Markets Insider reported that ResMed generated USD 1.46 billion of revenue and USD 383.43 million of net profit in the quarter ended June 30, 2026, compared with USD 1.35 billion and USD 379.71 million a year earlier. The report also said quarterly earnings per share reached USD 2.95 versus a USD 2.89 consensus estimate.
Analyst target meets a cautious consensus
The RBC upgrade contrasts with the broader rating balance. MarketBeat said nine analysts held a Hold rating and seven rated the stock Buy, producing a consensus Hold view and an average 12-month target of USD 241.69.
That split matters because the operating figures remain positive while valuation depends on continued execution. ResMed serves the sleep and respiratory care market through devices, masks, connected health products and software, with operations reaching more than 140 countries.
The euro quote remains above the prior close
ResMed stock was trading at EUR 199.38 at Lang & Schwarz on October 6, 2026 at 4:01 p.m. CEST, up 0.57 percent versus the Lang & Schwarz prior close of EUR 198.25 on October 5, 2026. The primary listing is on the NYSE, where the finance quote showed USD 224.05 on October 6, 2026 at 10:02 a.m. EDT, with a 52-week range of USD 180.27 to USD 284.87 and market capitalization of USD 32.5 billion.
The further course of trading is shown by the continuously updated real-time quote of ResMed stock.
ResMed stock facts on October 6, 2026
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 6, 2026, 4:01 p.m. CEST): EUR 199.38
- Change versus prior close: plus 0.57 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 198.25
- Market capitalization: USD 32.5 billion (as of October 6, 2026)
- 52-week range: USD 180.27-284.87 (as of October 6, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
